Global

CN EN
ABOUT US
GROUND-BREAKING THERAPEUTICS

Scroll down to see more

About Laekna

Stock Code: 2105.HK


Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapies to patients with cancer, liver fibrosis and metabolic diseases.


As of June 30, 2023, Laekna has initiated six clinical trials for Afuresertib (LAE002), LAE001 and LAE005 to address unmet medical needs in cancers, such as ovarian cancer, breast cancer and prostate cancer. Among the six clinical trials, three are multi-regional clinical trials (MRCTs) , including one pivotal trial.


Laekna’s internal drug discovery platform has discovered 12 drug candidates. LAE102 is our first internally discovered antibody which has obtained the IND approval from FDA. Its potential indications include muscle regeneration, obesity and cancer.


Laekna, Inc. was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023, the stock code is 2105.HK.

Our Vision
Our Vision

We are committed to becoming
a biopharmaceutical company
that can bring novel therapies
to patients with cancer, liver fibrosis
and metabolic diseases.

Core Management Team
Milestones
Scientific Advisory Board
Peter ten Dijke
Back
  • Last :Peter ten Dijke
  • Next :Jeff Porter
Core Inverstors
Honors & Awards
  • 2023

    Zhangjiang Life Science Industry New Prominent

    2023 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Annual Innovation Award

    Most Valuable Pharmaceutical and Healthcare Company

    bioPR 2023 Best Corporate Video

    ZHANGJIANG GROUP Annual Influential Tech-Inno Startup

  • 2022

    2022 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    2022 Pioneers: The Scientists

    KPMG China Future 50 - Biotech

  • 2021

    2021 China Corporate Social Responsibility Virtual Summit - CSR Good Practice

    2021 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Pioneers to the Star 2021 Biomedicine Pioneer-10

    Frost & Sullivan 2021 Top 100 Technology Leaders - Top 50 Innovative Technology Leaders

  • 2020

    Top 20 Disruptive Technologies in Cancer

  • 2019

    China Healthcare Industry Investment and Financing Honor List: Top 20 Emerging Healthcare Companies

  • 2018

    2018 Insights Zhangjiang Top 100

More
图片1
图片2
图片3 图片4
图片5
图片6
图片7
图片8
图片9
Back
  • Last:Peter ten Dijke
  • Next:Jeff Porter
Back
  • Last:Peter ten Dijke
  • Next:Jeff Porter
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin